Explore the latest in myeloma, including recent advances in diagnosis and management of monoclonal gammopathy and multiple myeloma.
This cohort study assesses the concordance of 3 models to stratify risk for progression to multiple myeloma in an independent cohort of patients with smoldering multiple myeloma.
This systematic review and meta-analysis assesses the association of the addition of daratumumab to backbone multiple myeloma regimens with progression-free survival among patients with cytogenetically defined high-risk multiple myeloma.
This review summarizes current clinical challenges and discusses available models for risk stratification in the context of smoldering multiple myeloma.
This cohort study compares the use of different bone-modifying agents among Medicare beneficiaries with multiple myeloma.
This case-control study examines the association of Listeria monocytogenes susceptibility with the receipt of daratumamab-based therapy in Canadian patients with multiple myeloma.
In this narrative medicine essay, a palliative care physician reconsiders the meaning of the “What are your most important goals if time were short?” question when it is posed to her mother who has refractory multiple myeloma.
This cohort study investigates the association of prediagnostic serum immune markers with the subsequent diagnosis of stable monoclonal gammopathy of undetermined significance vs progression to multiple myeloma.
A woman in her late 60s presented with progressive, painless blurring of vision in both eyes. She had bilateral, gray-white, irregular, poorly circumscribed, linear and nummular central and peripheral corneal opacities. What would you do next?
This Viewpoint presents 4 arguments against routinely substituting zoledronic acid with denosumab in patients with newly diagnosed multiple myeloma.
This case report describes a 73-year-old man with multiple myeloma who presented with bilateral foggy vision and visual field constrictions while he was taking daratumumab.
This case report describes a patient with systemic amyloidosis.
A 60-year-old man with a history of IgA kappa multiple myeloma was referred for evaluation of an indolent, erythematous papule on his glans penis of 2 weeks’ duration; he denied sexual risk behavior and reported no recent changes in medication. What is your diagnosis?
This cohort study study examines the incidence of secondary hematologic malignant neoplasms among French women after breast cancer diagnosis or treatment.
This case report describes a diagnostically challenging electrocardiography finding after apparent chemotherapy infusion reaction.
This nonrandomized clinical trial examines the safety, tolerability, immunogenicity, and anti–multiple myeloma activity of the PVX-410 multipeptide vaccine with or without lenalidomide.
This 5-year follow-up of a phase 2 clinical trial assesses long-term durability of minimal residual disease–negative remission and time to disease progression among patients with newly diagnosed multiple myeloma who received triplet-based induction therapy with lenalidomide maintenance therapy.
This Clinical Evidence Synopsis summarizes a Cochrane review of randomized trials comparing the effects of bisphosphonate therapy vs placebo or no treatment on mortality, vertebral fractures, nonvertebral fractures, and skeletal-related events among patients with multiple myeloma.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: